Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia(2022)10.1016/j.clml.2022.07.002Source: DataRank Database

Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2022). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

6 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.89)OA: closedTopics (40)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Andrzej Jakubowiak ORCID,Benjamin A. Derman ORCID,Ajay Major ORCID

Live enrichment

PubMed:35922273 OpenAlex:https://openalex.org/W4285013092

National Cancer Institute

Grant: T32CA009566

National Institutes of Health

Multiple Myeloma Research Foundation

Minneapolis Medical Research Foundation

FWCI

0.89

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S2152265022002191?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265022002191?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clml.2022.07.002

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35922273

Fields of Study

Multiple Myeloma Research and TreatmentsCancer Treatment and PharmacologyChronic Myeloid Leukemia TreatmentsHumansLenalidomideBortezomibMultiple MyelomaMelphalanHematopoietic Stem Cell TransplantationQuality of LifeTransplantation, AutologousDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamidePeripheral Nervous System DiseasesPatient Reported Outcome Measures

MeSH Terms

BortezomibPatient Reported Outcome MeasuresLenalidomideAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDexamethasoneHumansMelphalanMultiple MyelomaPeripheral Nervous System DiseasesQuality of LifeTransplantation, AutologousHematopoietic Stem Cell Transplantation

Keywords

MedicineLenalidomideBortezomibMultiple myelomaOncologyInternal medicineQuality of lifeMelphalanPeripheral NeuropathyAutologous TransplantationReal-world Data

Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma

FAIR Checklist

Authors (3)

Funding (4 grants)

Impact

Open Access

Topics